# Greg Garfield

> Greg Garfield is a Series D investor at KCK (Menlo Park) backing Health Care and Medical Device. See 7 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [KCK](https://shizune.co/investors/profile/kck)
- Location: Menlo Park, United States
- Total investments: 7
- Last investment: Mar 2022
- Lead investor: 43%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/greg-garfield-4126b14/

Greg Garfield is a Series D investor at KCK in Menlo Park focused on Health Care and Medical Device. Greg is an executive with extensive experience in running medical technology companies, including managing and leading people at all levels, as well operational management and business strategy and planning.Originally an attorney at Pillsbury Winthrop, Greg began his medical technology career at Guidant Corporation where he held a number ofexecutive-level legal and business development positions in different Guidant operating companies. Following Guidant's acquisition by Boston Scientific, Greg joined Acclarent, Inc. where he served initially as Vice President of Corporate Development, and then as Acclarent's Chief Operating Officer through the acquisition and integration of Acclarent by Ethicon, Inc., a Johnson & Johnson company.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 3 | 43% |
| Medical Device | 3 | 43% |
| Medical | 2 | 29% |
| Neuroscience | 1 | 14% |
| Therapeutics | 1 | 14% |

7 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series D | 2 | 29% |
| Series B | 1 | 14% |
| Series C | 1 | 14% |
| Series E | 1 | 14% |
| Funding Round | 1 | 14% |

6 stages tracked in total.

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| RefleXion Medical | RefleXion is developing the first biology-guided radiotherapy system, a significant change in strategy from single tumor therapy to the ability to one day treat multiple tumors in the same treatment session in cancers that have metastasized. Currently, the RefleXion X1 machine is cleared for the delivery of stereotactic body radiotherapy (SBRT),stereotactic radiosurgery (SRS) and intensity modulated radiotherapy (IMRT). The company is also developing BgRT, which incorporates positron-emission tomography (PET) imaging data to enable tumors to continuously signal their location. The BgRT technology will synchronize these data with the linear accelerator to direct radiotherapy to tumors with subsecond latency. | $80M | Series E | Mar 10, 2022 |  |
| NeuroPace | NeuroPace designs develops, manufactures, and markets implantable devices for the treatment of neurological disorders. It offers a responsive Neurostimulator system (RNS) for the treatment of medically refractory partial epilepsy. The company's RNS system consists of implantable components, including RNS neurostimulator that delivers a shorttrain of electrical pulses to the brain, and depth leads and cortical strip leads; and external products, such as the programmer, a laptop computer with proprietary software that has a wand and telemetry interface enabling communication with an implanted RNS neurostimulator. NeuroPace was incorporated in 1997 and is based in Mountain View, California. | $33M | Venture - Series Unknown | Aug 31, 2020 |  |
| RefleXion Medical | RefleXion is developing the first biology-guided radiotherapy system, a significant change in strategy from single tumor therapy to the ability to one day treat multiple tumors in the same treatment session in cancers that have metastasized. Currently, the RefleXion X1 machine is cleared for the delivery of stereotactic body radiotherapy (SBRT),stereotactic radiosurgery (SRS) and intensity modulated radiotherapy (IMRT). The company is also developing BgRT, which incorporates positron-emission tomography (PET) imaging data to enable tumors to continuously signal their location. The BgRT technology will synchronize these data with the linear accelerator to direct radiotherapy to tumors with subsecond latency. | $100M | Series D | Apr 17, 2020 |  |
| Earlens | Earlens is a privately held medical technology company committed to transforming the hearing experience for millions of people who suffer from hearing loss.The company has developed the Earlens Contact Hearing Solution, which directly activates natural hearing, delivering the broadest bandwidth available today and superior sound quality. Thisrevolutionary, non-surgical hearing solution uses a small lens to vibrate the eardrum, replicating the natural hearing process. The Earlens Contact Hearing Solution received FDA clearance in 2019 for a second generation of the Earlens technology. Unlike traditional hearing aids, which are in effect tiny speakers that simply turn up the volume on air conducted sound, the Earlens Contact Hearing Solution™ is the world’s first to deliver sound directly to the eardrum. | $87M | Series D | Oct 22, 2018 |  |
| RefleXion Medical | RefleXion is developing the first biology-guided radiotherapy system, a significant change in strategy from single tumor therapy to the ability to one day treat multiple tumors in the same treatment session in cancers that have metastasized. Currently, the RefleXion X1 machine is cleared for the delivery of stereotactic body radiotherapy (SBRT),stereotactic radiosurgery (SRS) and intensity modulated radiotherapy (IMRT). The company is also developing BgRT, which incorporates positron-emission tomography (PET) imaging data to enable tumors to continuously signal their location. The BgRT technology will synchronize these data with the linear accelerator to direct radiotherapy to tumors with subsecond latency. | $100M | Series C | Apr 04, 2018 |  |
| NeuroPace | NeuroPace designs develops, manufactures, and markets implantable devices for the treatment of neurological disorders. It offers a responsive Neurostimulator system (RNS) for the treatment of medically refractory partial epilepsy. The company's RNS system consists of implantable components, including RNS neurostimulator that delivers a shorttrain of electrical pulses to the brain, and depth leads and cortical strip leads; and external products, such as the programmer, a laptop computer with proprietary software that has a wand and telemetry interface enabling communication with an implanted RNS neurostimulator. NeuroPace was incorporated in 1997 and is based in Mountain View, California. | $74M |  | Oct 24, 2017 |  |
| RefleXion Medical | RefleXion is developing the first biology-guided radiotherapy system, a significant change in strategy from single tumor therapy to the ability to one day treat multiple tumors in the same treatment session in cancers that have metastasized. Currently, the RefleXion X1 machine is cleared for the delivery of stereotactic body radiotherapy (SBRT),stereotactic radiosurgery (SRS) and intensity modulated radiotherapy (IMRT). The company is also developing BgRT, which incorporates positron-emission tomography (PET) imaging data to enable tumors to continuously signal their location. The BgRT technology will synchronize these data with the linear accelerator to direct radiotherapy to tumors with subsecond latency. | $52M | Series B | Apr 14, 2016 |  |

7 of 7 investments shown.

## Co-investors
- [Pfizer Venture Investments](https://shizune.co/investors/profile/pfizer-venture-investments) — VC Fund, 4 deals together
- [Venrock](https://shizune.co/investors/profile/venrock) — VC Fund, 4 deals together
- [Sofinnova Partners](https://shizune.co/investors/profile/sofinnova-partners) — VC Fund, 3 deals together
- [The Rise Fund](https://shizune.co/investors/profile/the-rise-fund) — VC Fund, 3 deals together
- [T. Rowe Price](https://shizune.co/investors/profile/t-rowe-price) — VC Fund, 3 deals together
- [Johnson & Johnson Robotics and Digital Solutions](https://shizune.co/investors/profile/johnson-johnson-innovation) — VC Fund, 2 deals together

## About KCK

VC Fund · New York, United States

KCK is a family investment fund that invests in a diverse set of industries, including medical technologies. KCK interests in Life Sciences - Biopharm/ Biotech & MedTech, Energy, Science-rich companies and Industrial Technologies. KCK invest at all stages of a startup's from early stage to growth rounds and also invest in publiccompanies. KCK is the private equity arm of a family office which seeks to partner with experienced management teams, focused on niche markets, deploying long-term flexible capital to generate high risk-adjusted returns.

2 contacts available at KCK.

| Name | Title | Profile |
| --- | --- | --- |
| Greg Garfield | Senior Managing Director | https://shizune.co/investors/profile/greg-garfield |
| Nael Kassar | Founder | https://shizune.co/investors/profile/nael-kassar |

## Similar investors

### Similar stage
- [Sigma Partners](https://shizune.co/investors/profile/sigma-partners) — VC Fund
- [EDBI](https://shizune.co/investors/profile/edbi) — VC Fund
- [Trifecta Capital Advisors](https://shizune.co/investors/profile/trifecta-capital-advisors) — VC Fund

## FAQ

### What does Greg Garfield invest in?

Greg Garfield invests primarily in Health Care, Medical Device and Medical startups, most often at Series D and Series B stage. Most of the 7 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Greg Garfield last invest?

The most recent investment recorded for Greg Garfield closed in Mar 2022. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co